Predisposing factors of hysteromyoma and effect of hualiu recipe on it.
- Author:
Lei TAN
1
;
Wei MENG
;
Ting-ting ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Disease Susceptibility; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Medicine, Chinese Traditional; Middle Aged; Phytotherapy; Treatment Outcome; Uterine Neoplasms; diagnosis; drug therapy; epidemiology; Young Adult
- From: Chinese Journal of Integrated Traditional and Western Medicine 2011;31(5):635-638
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the clinical efficacy of hualiu recipe (HLR) in treating hysteromyoma, and to explore the correlation between the predisposing factors and the tumor volume as well as the therapeutic efficacy.
METHODSOne hundred and ten outpatients with hysteromyoma of qi deficiency blood stasis syndrome were enrolled, who were outpatients of Department of Gynecology, Shanghai Yueyang Hospital of Integrative Medicine from September 2005 to September 2007. Their predisposing factors were collected by questionnaire. They were randomly assigned to two groups. The eighty patients in the treatment group were treated with HLR, while the thirty patients in the control group were treated with Guizhi Fuling Capsule. The clinical efficacy and changes of uterus and tumor volumes before and after treatment, improvement of Chinese syndrome, and the correlation between the therapeutic efficacy and predisposing factors were observed.
RESULTSThe total effective rate in the treatment group was 85.0% (68/80), while that in the control group was 66.7% (20/30), showing statistical significance (P < 0.05). The therapeutic efficacy of patients with predisposing factors was better in the treatment group than in the control group, showing significant difference (P < 0.05). The tumor volume was observed to be positively correlated with the delivery age, the disease course, and the emotional stress. The clinical efficacy was negatively correlated with the disease course, the emotional stress, and the hyperplasia of mammary glands.
CONCLUSIONHLR could effectively reduce the tumor volume of hysteromyoma, and obviously improve clinical symptoms and accompanied disease. The therapeutic efficacy could be improved by prevention and treatment of predisposing factors.